New pathways are being identified now on a regular basis, and novel agents are being tested in a wide variety of clinical trials for patients with advanced non-small cell lung cancer. Excitement over progress in one area is tempered naturally by disappointing results in other areas. Each year, leading lung cancer experts meet in Santa Monica to discuss the progress in the field of molecularly targeted therapy in non-small cell lung cancer. Annual conferences similar to the one held in Santa Monica serve mainly as a catalyst to promote new ideas and foster active collaboration. We have invited participants to provide very brief succinct summaries of the presentations for this supplement. The articles in this supplement should be viewed more as meeting reports than as exhaustive and comprehensive review articles.
- Lung cancer
- Molecularly targeted therapies